Biocon (BIOCON.NS) Stock Price

Biocon Price

NSE·CLOSED
340.00
​
Market closed

Revenue has compounded at 16.9% per year over the past 19 years to 152.62 B INR. Earnings per share have grown at 8.9% per year over the last 19 years. Biocon's net margin stands at 6.6%, down from 10.4% several years earlier. Biocon currently offers a dividend yield of about 0.15%. The payout ratio is around 7% of earnings. The dividend has grown at 4.7% per year over the past 19 years. Analysts set a median price target of 450.84 INR, implying 32.6% above the current price. Of 18 analysts, 12 rate the stock a buy — an overall Buy consensus.

Biocon stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biocon business model & stock analysis

Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. The company is headquartered in Bangalore, Karnataka and currently employs 3,408 full-time employees. The company went IPO on 2004-04-17. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. The company has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. The company has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.

Frequently asked questions about Biocon

Analysts currently set an average price target of 439.62 INR for the Biocon stock (median: 450.84 INR), implying +29.3 % versus the latest price. The consensus is based on 18 analyst ratings.

18 analysts currently rate the Biocon stock: 12 recommend buying, 3 holding and 3 selling. For 2026, analysts expect Biocon to generate revenue of 169.99 B INR and earnings per share of 4.70 INR.

Converted at the current exchange rate, the Biocon share trades at 3.19 EUR (340.00 INR).

The Biocon share (BIOCON.NS) is listed on 2 stock exchanges, including: NSE (Indien) (BIOCON.NS).

The expected revenue of Biocon is 169.99 B INR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Biocon is 6.32 B INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Biocon is currently 72.33. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Biocon stock.

The price-to-sales ratio (P/S) of Biocon is currently 2.69. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Biocon stock.

The Eulerpool Quality Score for Biocon is 8/10.

The ISIN of Biocon is INE376G01013. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Biocon is BIOCON.NS. The ticker symbol is used to trade Biocon shares on the stock exchange.

Fair ValueTerminal
306.00 INR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
44.78 M INR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website biocon.com
Country
Currency
INR
Initial public offering
Apr 17, 2004
ISIN
INE376G01013
Cusip
Y0905C102
Market capitalization
550.57 B INRMega Cap
52-Week Range
PEG
1.18
P/E ratio
P/Ee 2026
87.16
P/Ee 2027
49.92
P/Ee 2028
31.05
P/Ee 2029
23.90
P/S
P/Se
2.69
EV/EBIT
23.55
P/B Ratio
2.54
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
2.66 %
Dividend
Dividend yield
0.15 %
Est. Dividend Yield
0.15 %
Payout Ratio
6.63 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
4 years
Dividend not reduced since
1 year
Dividend increased since
0 years
Dividend withholding tax
20.00 %
Last updated Oct 20, 2026, 7:50 AM

Biocon Peer Group

Biocon Ticker

BSE · BIOCON.BONSE INDIA · BIOCON.NS

Biocon FIGI

BIOS:IN · BBG000BJHB11BIOS:IB · BBG000BJHBC9BIOS:IS · BBG000BJHC64BIOS:IG · BBG003NW32Q1BIOSINR:EO · BBG01FG82BV9BIOSINR:X2 · BBG01FG82BW8BIOSINR:XH · BBG01FG82BY6BIOSINR:XF · BBG01FG82C01BIOSINR:XE · BBG01FG82C29BIOSINR:XJ · BBG01FG82C38BIOSINR:XL · BBG01FG82C47BIOSINR:XG · BBG01FG82C56

All fundamentals and in-depth analysis of Biocon

Our stock analysis for Biocon stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biocon. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.